top of page

Rafarma Pharmaceuticals registers CEFTRIAXONE under international label

Rafarma Pharmaceuticals, Inc. (OTC: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.

CEFTRIAXONE is most often used in combination for the treatment of pneumonia, bacterial meningitis, gonorrhea, and in pediatrics for the prevention of sepsis. Market capacity of CEFTRIAXONE in the Russian Federation in 2012 was USD $85.7 million dollars, an increase of 20% compared to its capacity in 2011.

Dave Anderson, CEO of Rafarma Pharmaceuticals, said, "Registering this product is complementary to our goal of producing high-quality pharmaceutical products. Rafarma is positioned to meet rising market demand for CEFTRIAXONE utilizing our state-of-the-art research facility and staff as we continue efforts to expand our product portfolio."

"I'd also like to clarify that Rafarma's earlier announcement reporting its status as 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation in no way limits our ability to produce and manufacture products for qualified buyers globally," added Mr. Anderson. "We will offer CEFTRIAXONE, as well as all other products we produce, to the international market."


Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in our annual report and/or other releases made by us. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Rafarma Pharmaceuticals, Inc. undertakes no obligation to update such statements.

SOURCE: Rafarma Pharmaceuticals, Inc.


bottom of page